This site is intended for health professionals only

Anticoagulant race hots up


The race to get a new class of oral anticoagulants onto the market may be being led by Bayer and Johnson & Johnson’s rivaroxaban, but Bristol-Myers Squibb and Pfizer’s apixaban may not be too far behind.

B-MS has just made public positive phase II data for apixaban, a new, direct-acting inhibitor of coagulation factor Xa, which was evaluated in patients with confirmed deep-vein thrombosis.

According to the data, presented at the International Society on Thrombosis and Haemostasis meeting in Geneva, 520 patients were allocated to one of three groups

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine